Year 2020 / Volume 112 / Number 11
Original
Serum miR-21 and miR-210 as promising non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer

832-837

DOI: 10.17235/reed.2020.6801/2019

Gang Li, Qi Wang, Zhenjun Li, Yi Shen,

Abstract
Objective: this study aimed to investigate the expression and clinical significance of miR-21 and miR-210 in serum of patients with colorectal cancer (CRC). Methods: the expression levels of serum miR-21 and miR-210 in 40 CRC patients (CRC group) and 20 healthy patients (control group) were measured by qRT-PCR. Correlation analysis was performed of the relationship between serum miR-21 and miR-210 levels with clinical characteristics, including gender, age, tumor location, tumor size, tumor stage, local invasion and TNM staging. The expression levels of miR-21 and miR-210 in the CRC group were separately measured before and after surgery. ROC analysis was performed to evaluate the diagnostic value of miR-21 and miR-210. Results: serum miR-21 and miR-210 in the CRC group were much higher than those in the control group. Meanwhile, the levels of serum miR-21 and miR-210 were closely related to tumor size (p = 0.028, p = 0.047), lymphatic metastasis (p = 0.038, p = 0.028), TNM staging (p = 0.014, p = 0.047) and tumor stage (p = 0.014, p = 0.017), but independent of gender, age and tumor location. In addition, serum miR-21 and miR-210 in the CRC group (n = 18) after surgery were lower than those before surgery (p < 0.001). ROC curves showed that miR-21 (AUC = 0.863) and miR-210 (AUC = 0.818) both had diagnostic efficacy in CRC patients. Conclusion: miR-21 and miR-210 can be used as novel non-invasive biomarkers for CRC diagnosis and prognosis.
Share Button
New comment
Comments
No comments for this article
References
1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A: Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians 2017, 67(3):177-193.
2. Siegel RL, Miller KD, Jemal A: Cancer Statistics, 2017. CA: a cancer journal for clinicians 2017, 67(1):7-30.
3. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A, Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer 2018.
4. Butterworth AS, Higgins JP, Pharoah P: Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. European journal of cancer 2006, 42(2):216-227.
5. Brenner H, Kloor M, Pox CP: Colorectal cancer. Lancet 2014, 383(9927):1490-1502.
6. Fakih MG, Padmanabhan A: CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park) 2006, 20(6):579-587; discussion 588, 594, 596 passim.
7. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105(30):10513-10518.
8. Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW: Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 2011, 6(6):e20769.
9. Ameres SL, Zamore PD: Diversifying microRNA sequence and function. Nature reviews Molecular cell biology 2013, 14(8):475-488.
10. Friedman RC, Farh KK, Burge CB, Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome research 2009, 19(1):92-105.
11. van Kouwenhove M, Kedde M, Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nature reviews Cancer 2011, 11(9):644-656.
12. Lu J, Zhan Y, Feng J, Luo J, Fan S: MicroRNAs associated with therapy of non-small cell lung cancer. International journal of biological sciences 2018, 14(4):390-397.
13. Wang H, Peng R, Wang J, Qin Z, Xue L: Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clinical epigenetics 2018, 10:59.
14. Hosseinahli N, Aghapour M, Duijf PHG, Baradaran B: Treating cancer with microRNA replacement therapy: A literature review. Journal of cellular physiology 2018, 233(8):5574-5588.
15. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-297.
16. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA: MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8(8):467-477.
17. Nunez Lopez YO, Victoria B, Golusinski P, Golusinski W, Masternak MM: Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes. Rep Pract Oncol Radiother 2018, 23(1):6-20.
18. Kolenda T, Guglas K, Rys M, Bogaczynska M, Teresiak A, Blizniak R, Lasinska I, Mackiewicz J, Lamperska KM: Biological role of long non-coding RNA in head and neck cancers. Rep Pract Oncol Radiother 2017, 22(5):378-388.
19. Chen X, Liang H, Zhang J, Zen K, Zhang CY: Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 2012, 22(3):125-132.
20. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(30):10513-10518.
21. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic oncology 2009, 112(1):55-59.
22. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British journal of haematology 2008, 141(5):672-675.
23. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ: Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58(10):1375-1381.
24. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, Lo YM: Detection and characterization of placental microRNAs in maternal plasma. Clinical chemistry 2008, 54(3):482-490.
25. Luo X, Burwinkel B, Tao S, Brenner H: MicroRNA signatures: novel biomarker for colorectal cancer?Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011, 20(7):1272-1286.
26. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J et al: Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. The Lancet Oncology 2013, 14(13):1295-1306.
27. Vychytilova-Faltejskova P, Radova L, Sachlova M, Kosarova Z, Slaba K, Fabian P, Grolich T, Prochazka V, Kala Z, Svoboda M et al: Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis 2016, 37(10):941-950.
28. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W, Chen K: Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One 2013, 8(11):e77853.
29. Schee K, Boye K, Abrahamsen TW, Fodstad O, Flatmark K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC cancer 2012, 12:505.
30. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S: Plasma miR-21: a potential diagnostic marker of colorectal cancer. Annals of surgery 2012, 256(3):544-551.
31. Li M, Ma X, Li M, Zhang B, Huang J, Liu L, Wei Y: Prognostic role of microRNA-210 in various carcinomas: a systematic review and meta-analysis. Disease markers 2014, 2014:106197.
32. Xie X, Wu W, Liang L, Han S, Chen T, Pan S, Xue M, Li S: Prognostic role of microRNA-210 in various carcinomas: a meta-analysis. International journal of clinical and experimental medicine 2015, 8(9):15283-15289.
33. Fouad H, Sabry D, Morsi H, Shehab H, Abuzaid NF: XRCC1 Gene Polymorphisms and miR-21 Expression in Patients with Colorectal Carcinoma. The Eurasian journal of medicine 2017, 49(2):132-136.
34. Qu A, Du L, Yang Y, Liu H, Li J, Wang L, Liu Y, Dong Z, Zhang X, Jiang X et al: Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PloS one 2014, 9(3):e90952.
35. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72(5-6):397-402.
36. Li M, Zou X, Xia T, Wang T, Liu P, Zhou X, Wang S, Zhu W: A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med 2019, 8(16):7006-7017.
37. Yu W, Wang Z, Shen LI, Wei Q: Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: A meta-analysis. Mol Clin Oncol. 2016;4(2):237–244.
38. Das V, Kalita J, Pal M: Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. Biomed Pharmacother. 2017;87:8–19.
Related articles

Letter

Vaginal lesion as first manifestation of colorectal disease

DOI: 10.17235/reed.2022.9270/2022

Review

Inflammatory bowel disease and solid organ transplantation

DOI: 10.17235/reed.2020.7361/2020

Review

New non-invasive biomarkers for colorectal cancer screening

DOI: 10.17235/reed.2020.7233/2020

Letter

Medullary colorectal carcinoma. Do we really know it?

DOI: 10.17235/reed.2020.6728/2019

Letter

The rectosigmoid junction: are limits important?

DOI: 10.17235/reed.2019.5983/2018

Editorial

Colorectal cancer screening and survival

DOI: 10.17235/reed.2018.5870/2018

Letter to the Editor

Liver metastasis from colorectal cancer 12 years after liver transplantation

DOI: 10.17235/reed.2017.4507/2016

Review

Serrated lesions and serrated polyposis syndrome

DOI: 10.17235/reed.2017.4065/2015

Letter to the Editor

Endobronchial metastases of colorectal cancer

DOI: 10.17235/reed.2016.4080/2015

Citation tools
Li G, Wang Q, Li Z, Shen Y. Serum miR-21 and miR-210 as promising non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer. 6801/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 837 visits.
This article has been downloaded 156 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 09/12/2019

Accepted: 27/02/2020

Online First: 15/10/2020

Published: 10/11/2020

Article revision time: 62 days

Article Online First time: 311 days

Article editing time: 337 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology